We advised ADC Therapeutics on the equity offering

Davis Polk advised ADC Therapeutics SA in connection with a private placement of 13,031,161 of its common shares at a price of $3.53 per share and, in lieu of common shares, pre-funded warrants to purchase up to 15,734,267 common shares at a price of $3.43 per pre-funded warrant.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. ADC Therapeutics is based in Lausanne (Biopôle), Switzerland, and has operations in London and New Jersey. ADC Therapeutics is listed on the NYSE under the symbol “ADCT.”

The Davis Polk capital markets team included partners Yasin Keshvargar and Deanna L. Kirkpatrick, counsel David (Wei Fu) Li and associates Agustin N. Lopez Roualdes and Yuchen Liu. All members of the Davis Polk team are based in the New York office.

Copy link to share post